[1] TAN A C,ASHLEY D M,LÓPEZ G Y,et al.Management of glioblastoma:state of the art and future directions[J].CA Cancer J Clin,2020,70(4):299-312.
[2] OGBU II.Glioblastoma:intraoperative monitoring and tumour classification[J].Bmj,2021,374:n2095.
[3] SCHAFF L R,MELLINGHOFF I K.Glioblastoma and other primary brain malignancies inadults:a review[J].Jama,2023,329(7):574-587.
[4] WYKES V,ZISAKIS A,IRIMIA M,et al.Importance and evidence of extent of resection in glioblastoma[J].J Neurol Surg A Cent Eur Neurosurg,2021,82(1):75-86.
[5] WEN P Y,WELLER M,LEE E Q,et al.Glioblastoma in adults:a society for neuro-oncology(SNO) and European society of neuro-oncology(EANO) consensus review on current management and future directions[J].Neuro Oncol,2020,22(8):1073-1113.
[6] FOUNTAIN D M,BRYANT A,BARONE D G,et al.Intraoperative imaging technology to maximise extent of resection for glioma:a network meta-analysis[J].Cochrane Database Syst Rev,2021,1(1):Cd013630.
[7] CONTI NIBALI M,GAY L G,SCIORTINO T,et al.Surgery for glioblastoma in elderly patients[J].Neurosurg Clin N Am,2021,32(1):137-148.
[8] SALLE H,DELUCHE E,COUVÉ-DEACON E,et al.Surgical site infections after glioblastoma surgery:results of a multicentric retrospective study[J].Infection,2021,49(2):267-275.
[9] BATTISTA F,MUSCAS G,DINOI F,et al.Ventricular entry during surgical resection is associated with intracranial leptomeningeal dissemination in glioblastoma patients[J].J Neurooncol,2022,160(2):473-480.
[10] MELNICK K,MILLER P,CARMICHAEL E,et al.Histologic findings at the time of repeat resection predicts survival in patients with glioblastoma[J].World Neurosurg,2022,168:e451-e459.
[11] JUSUE-TORRES I,LEE J,GERMANWALA A V,et al.Effect of extent of resection on survival of patients with glioblastoma,IDH-wild-type,WHO grade 4(WHO 2021):systematic review and Meta-analysis[J].World Neurosurg,2023,171:e524-e532.
[12] 宋旭东,罗波,陈华轩,et al.miR-105联合MMP-2预测脑胶质瘤术后复发的临床价值分析[J].东南大学学报(医学版),2022,41(5):615-623.
[13] KAWAUCHI D,OHNO M,MIYAKITA Y,et al.Early diagnosis and surgical intervention within 3 weeks from symptom onset are associated with prolonged survival of patients with glioblastoma[J].Neurosurgery,2022,91(5):741-778.
[14] SHI X,LI H,XU Y,et al.The prognostic value of the preoperative inflammatory index on the survival of glioblastoma patients[J].Neurol Sci,2022,43(9):5523-5531.
[15] WELLER M,VAN DEN BENT M,PREUSSER M,et al.EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood[J].Nat Rev Clin Oncol,2021,18(3):170-186.
[16] SAITO R.Chemotherapy for glioma[J].No Shinkei Geka,2021,49(3):588-596.
[17] WEN J,CHEN W,ZHU Y,ZHANG P.Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma(GBM):a surveillance,epidemiology,and end results(SEER) analysis[J].BMC Cancer,2021,21(1):81.
[18] FIORICA F,COLELLA M,TAIBI R,et al.Glioblastoma:prognostic factors and predictive response to radio and chemotherapy[J].Curr Med Chem,2020,27(17):2814-2825.
[19] ZHAO M,VAN STRATEN D,BROEKMAN M L D,et al.Nanocarrier-based drug combination therapy for glioblastoma[J].Theranostics,2020,10(3):1355-1372.
[20] SONG Q,PENG S,CHE F,ZHU X.Artesunate induces ferroptosis via modulation of p38 and ERK signaling pathway in glioblastoma cells[J].J Pharmacol Sci,2022,148(3):300-306.
[21] JI M,WANG L,CHEN J,et al.CAT(3),a prodrug of 13a(S)-3-hydroxyl-6,7-dimethoxyphenanthro[9,10-b]-indolizidine,circumvents temozolomide-resistant glioblastoma via the Hedgehog signaling pathway,independently of O(6)-methylguanine DNA methyltransferase expression[J].Onco Targets Ther,2018,11:3671-3684.
[22] HERRLINGER U,TZARIDIS T,MACK F,et al.Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter(CeTeG/NOA-09):a randomised,open-label,phase 3 trial[J].Lancet,2019,393(10172):678-688.
[23] HOTCHKISS K M,SAMPSON J H.Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor[J].J Neurooncol,2021,151(1):55-62.
[24] LOMBARDI G,DE SALVO G L,BRANDES A A,et al.Regorafenib compared with lomustine in patients with relapsed glioblastoma(REGOMA):a multicentre,open-label,randomised,controlled,phase 2 trial[J].Lancet Oncol,2019,20(1):110-119.
[25] LIM M,WELLER M,IDBAIH A,et al.Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter[J].Neuro Oncol,2022,24(11):1935-1949.
[26] ESKILSSON E,RØSLAND G V,SOLECKI G,et al.EGFR heterogeneity and implications for therapeutic intervention in glioblastoma[J].Neuro Oncol,2018,20(6):743-752.
[27] LE RHUN E,PREUSSER M,ROTH P,et al.Molecular targeted therapy of glioblastoma[J].Cancer Treat Rev,2019,80:101896.
[28] KALEY T,TOUAT M,SUBBIAH V,et al.BRAF Inhibition in BRAF(V600)-mutant gliomas:results from the VE-BASKET study[J].J Clin Oncol,2018,36(35):3477-3484.
[29] LASSMAN A,PUGH S,WANG T,et al.ACTR-21.A randomized,double-blind,placebo-controlled phase 3 trial of depatuxizumab MAFODOTIN(ABT-414) In epidermal growth factor receptor(EGFR) amplified(AMP) newly diagnosed glioblastoma(nGBM)[J].Neuro Oncol,2019,21(Suppl 6):vi17.
[30] MISHRA R,PATEL H,ALANAZI S,et al.PI3K Inhibitors in Cancer:Clinical Implications and Adverse Effects[J].Int J Mol Sci,2021,22(7):3464.
[31] WEN P Y,RODON J A,MASON W,et al.Phase I,open-label,multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma[J].ESMO Open,2020,5(4):e000673.
[32] LASSMAN A B,WEN P Y,VAN DEN BENT M J,et al.A Phase II study of the efficacy and safety of oral selinexor in recurrent glioblastoma[J].Clin Cancer Res,2022,28(3):452-460.
[33] BAUSART M,PRÉAT V,MALFANTI A.Immunotherapy for glioblastoma:the promise of combination strategies[J].J Exp Clin Cancer Res,2022,41(1):35.
[34] YAO Y,LUO F,TANG C,et al.Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma:an exploratory randomized phase II clinical trial[J].Cancer Immunol Immunother,2018,67(11):1777-1788.
[35] MIGLIORINI D,DUTOIT V,ALLARD M,et al.Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients[J].Neuro Oncol,2019,21(7):923-933.
[36] COBB D A,DE ROSSI J,LIU L,et al.Targeting of the alpha(v) beta(3) integrin complex by CAR-T cells leads to rapid regression of diffuse intrinsic pontine glioma and glioblastoma[J].J Immunother Cancer,2022,10(2):e003816.
[37] VITANZA N A,JOHNSON A J,WILSON A L,et al.Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors:an interim analysis[J].Nat Med,2021,27(9):1544-1552.
[38] REARDON D A,KIM T M,FRENEL J S,et al.Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma:Results from the multicohort phase 1 KEYNOTE-028 trial[J].Cancer,2021,127(10):1620-1629.
[39] HILF N,KUTTRUFF-COQUI S,FRENZEL K,et al.Actively personalized vaccination trial for newly diagnosed glioblastoma[J].Nature,2019,565(7738):240-245.
[40] REARDON D A,BRANDES A A,OMURO A,et al.Effect of Nivolumab vs Bevacizumab in patients with recurrent glioblastoma:the checkMate 143 phase 3 randomized clinical trial[J].JAMA Oncol,2020,6(7):1003-1010.
[41] PRZYSTAL J M,WARAMIT S,PRANJOL M Z I,et al.Efficacy of systemic temozolomide-activated phage-targeted gene therapy in human glioblastoma[J].EMBO Mol Med,2019,11(4):e8492.
[42] FU Z,ZHANG X,ZHOU X,et al.In vivo self-assembled small RNAs as a new generation of RNAi therapeutics[J].Cell Res,2021,31(6):631-648.
[43] KUMTHEKAR P,KO C H,PAUNESKU T,et al.A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma[J].Sci Transl Med,2021,13(584):eabb3945.
[44] CLOUGHESY T F,BRENNER A,DE GROOT J F,et al.A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma(GLOBE)[J].Neuro Oncol,2020,22(5):705-717. |
